Immutep TACTI-003 Phase IIb Eftilagimod Alpha Pembrolizumab HNSCC

TACTI-003 is a randomized Phase IIb trial evaluating eftilagimod alpha (LAG-3 agonist) combined with pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma. The study, sponsored by Immutep and conducted across 16 international sites, enrolls patients stratified by PD-L1 expression with primary objectives measuring objective response rate and overall survival.